PDS Biotechnology Corp (PDSB) Form S-3 — Oct 14, 2026
PDS Biotechnology filed an S-3 registering the resale of up to 110,001,540 shares by selling stockholders from its September 2026 private placement — nearly matching the 105,005,429 shares currently outstanding, creating potential dilution of more than 100% if warrants are exercised and sold. The registered shares comprise 16,502,870 initial shares, up to 73,498,156 pre-funded warrant shares, and 20,000,514 common warrant shares, sold at $0.2825 per unit for roughly $11.3 million in gross proceeds. An additional $11 million milestone closing (led by $10 million from Nant Capital) is committed upon FDA submission of a registrational Phase 3 protocol for PDS0301.
Key figures
- Gross Proceeds
- 11300290
- Offering Price
- 0.2825
- Shares Offered
- 110001540
- Shares Outstanding
- 105005429
- Initial shares
- 16502870
- Authorized shares
- 300000000
- Common warrant shares
- 20000514
- Liquidated damages rate
- 1.0% monthly, max 5.0%
- Workforce reduction pct
- 36%
- Closing price oct 13 2026
- 1.6
- Pre funded warrant shares
- 73498156
- Nant milestone subscription
- 10000000
- Milestone closing commitment
- 11000000
- Common warrant exercise price
- 0.22
- Redemption of april 2026 note
- 4600000
- Ab group milestone subscription
- 1000000
- Pre funded warrant exercise price
- 0.00033
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.